Posted by Adam Awdish on
Pooled Human Plasma Apheresis Derived from Innovative Research was used in the following study:
A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market
Andrew M. Brandon, Lysbeth H. Antonides, Jennifer Riley, Ola Epemolu, Denise A. McKeown, Kevin D. Read, and Craig McKenzie
March 5, 2021
A new, diverse group of synthetic drugs designed to activate human cannabinoid receptors CB1 and CB2 have emerged in the illicit drug market over recent years. These synthetic cannabinoid receptor agonists (SCRAs) have been linked to a variety of drug-related intoxication and death cases around the world. The intensity, duration, and exact effects of SCRAs can vary greatly between users and seem to be influenced by several factors such as the drug’s chemical makeup, the user’s age, their sex, body size, presence of other substances in their body, etc. Further, users often don’t even know the exact drug present and its concentration when using SCRAs.
This study investigated twelve different SCRAs that were found on the illicit drug market in hopes to better understand their structure, method of action, and physicochemical parameters. In vitro studies showed that these compounds broke down quickly in human plasma and liver metabolites, however in vivo observations showed potential accumulation of the compounds in fatty tissues. Additionally, these lipid-bound compounds may also redistribute back into the circulatory system for further metabolism and activation.
Related products available from Innovative Research also include: